Therapeutic antibodies
from EU-approved medicines

Currently, we offer 23 different therapeutic monoclonal antibodies from EU licensed drugs for use in R&D, preclinical development, process development, manufacturing & clinical development. Research-relevant quantities of the original drug are available as aliquot or dilution.

Drug name	Therapeutic molecule All molecules shown in this table are clinically approved by an international regulatory institution. However, all products sold by Evientic are for analytical / pre-clinical use only. Human use is prohibited! At this time (01/2020) all molecules available from Evidentic are licensed in the EU market.	Antigen	Manufacturer's CoA available What is a CoA? CoA is the abbreviation for 'Certificate of Analysis'. This document is in some cases supplied with originally manufactured pharmaceutical products, i.e. a drug. However, manufacturers of medicinal products for human use are not obliged to supply these documents and it therefore not easy to obtain the additional document. This document provides some basic data of a particular batch release and may help analytical scientists to prepare their characterization study. A new CoA is issued with each batch release of a manufacturer. Customers can purchase the available CoA for an additional charge. Legend: yes : CoAs for this product are available no : no CoA for each available batch no / yes: for most/some batches of a specific product CoAs can be obtained from Evidentic.
Avastin	Bevacizumab	VEGF-A	no ⋅ yes
Bavencio	Avelumab	PD-L1	no
CoA	Adalimumab ⋅ Atezolizumab ⋅ Avelumab ⋅ Bevacizumab ⋅ Cetuximab ⋅ Daratumumab ⋅ Denosumab ⋅ Durvalumab ⋅ Etanercept ⋅ Golimumab ⋅ Infliximab ⋅ Ipilimumab ⋅ Nivolumab ⋅ Obinutuzumab ⋅ Palivizumab ⋅ Pembrolizumab ⋅ Pertuzumab ⋅ Ramucirumab ⋅ Rituximab ⋅ Secukinumab ⋅ Tocilizumab ⋅ Trastuzumab ⋅ Ustekinumab		no ⋅ yes
Cosentyx	Secukinumab	IL 17A	no ⋅
Cyramza	Ramucirumab	VEGFR2	no
Darzalex	Daratumumab	CD38	no
Enbrel	Etanercept	TNF-α	no
Erbitux	Cetuximab	EGFR	no
Gazyvaro	Obinutuzumab	CD20	no
Herceptin	Trastuzumab	HER2	no
Humira	Adalimumab	TNF-α	no ⋅ yes
Imfinzi	Durvalumab	PD-L1	no
Keytruda	Pembrolizumab	PD-1	no ⋅ yes
Mabthera	Rituximab	CD20	no
Opdivo	Nivolumab	PD-1	no
Perjeta^new	Pertuzumab	HER2	no ⋅ yes
Prolia	Denosumab	RANKL	no
Remicade	Infliximab	TNF-α	no
RoActemra	Tocilizumab	IL-6 R	no
Simponi	Golimumab	TNF-α	no
Stelara	Ustekinumab	IL-12	no
Synagis	Palivizumab	RSV protein F	no ⋅ yes
Tecentriq^new	Atezolizumab	PD-L1	yes
Yervoy^new	Ipilimumab	CD152 ⋅ CTLA4	no ⋅ yes

Showing all 24 results

Signup for news and special offers!